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A subpopulation oflymphocytes expressing the CD3 proteins but not the a/o re-
ceptor has been identified recently. These cells represent ti5% of the lymphocytes
in human peripheral blood; they have been found to possess an additional type of
TCR that associates two chains designated y and 6. The corresponding proteins
are encoded by genes that rearrange specifically in T lymphocytes.
They chain locuswas the first to be characterized; it includes two C regions (Cyl
and Cy2) whose use determines whether the receptor is expressed as a disulfide-
linked (Cyl) or a non-disulfide-linked (Cy2) y/S heterodimer. TwoJ segments are
located upstream ofCy1 and three upstream ofCy2 (1-3). 14 Vy genes have been
described upstream of the Cyl region (4-6).
The S locus, identified more recently, is found between Va and Ca genes (7, 8);
one C region has been characterized with three D segments and three J segments
located upstream. Six VS genes have been described. Five are located upstream of
C6 (9-11); one ofthem belongs to the Va6 subfamily (12). One additional V seg-
ment lies downstream of CS in an inverted orientation (8, 11).
Several mAbs specific forvarioussegments ofthey/Sreceptor have been described.
AntiTCR-y/S-1 (13) recognizes a Cy-encoded antigenicdeterminant. AntiTCR-S1
reacts with a Cb-encoded epitope (14, 15). Thus, such reagents define the whole y/S+
fraction in a given cell suspension. The antiTiyA mAb (16) was found to recognize
theVy9 gene product (17). Anti-STCSI (18) islikely toreactwith anantigenic deter-
minant that includes V61 andJS1 (19), or V61 andJ62 (20). Anti-13133 was found
initially to recognize 6TCS1- cells expressing disulfide-linked receptors (21, 22); ad-
ditional experiments suggested that this mAb has a V62 specificity (10).
Thecharacterization ofanovel antibody, designated antiTiV62, is reported here.
It is shown that this reagent is specific for an epitope encoded by the V62 gene. In
addition, we have further investigated the reactivity of an additional mAb, termed
anti-A13 (23). This reagent has been described recently; it was found to recognize
a fraction of circulating y/S+ cells. These A13+ lymphocytes did not react with the
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anti-BB3 mAb while many of them were STCS1 + (23). Our data indicate that anti-
A13 is directed at an antigenic determinant encoded by the V61 gene.
The organization of the y/b' peripheral cell fraction has been reassessed here in
light of the reactivity of anti-A13 (VS1), anti-bTCS1 (VblJbl or V61-J62), and anti-
TiVb2 (Vb2) mAbs. It is shown that the expression of the 6TCS1 and the TiVb2
antigenic determinants accounts for the great majority of y/b+ circulating cells. In
certain donors, the summed reactivity of antiVbl and anti-V62 was greater than
that of antiTCRbl mAb. Experiments designed to understand this apparent dis-
crepancy led to the demonstration that the Vb1 segment is expressed with Ja-Ca
segments in a sizeable population of A13 + TCR-a/,f3+ peripheral lymphocytes.
Materials and Methods
Production of the Anti-TiVb2 Antibody.
￿
6-wk-old Biozzi mice were immunized with AB12
cells (10). The immunization schedule consisted of an intraperitoneal injection of 3 x 106
cells emulsified in CFA followed by three intraperitoneal injections of 3 x 106 cells emulsified
in IFA at 2-wk intervals. 2 wk later, 3 x 106 cells were injected intravenously in PBS, fol-
lowedby splenectomy 3 d later. Somatic hybridization was carried out as previously described
(24).
Generation and In Vitro Culture of Cell Lines.
￿
Some of the cell lines analyzed in this study
have been described previously. F6C7 and G6 clones were derived from peripheral blood
ofa 19-wk-old fetus(25-27). The other clones were obtained from PBL offour different adult
healthy donors (27, 28). The polyclonal cell line TH6.4 was derived from the peripheral blood
of a patient with a renal cell carcinoma. The A13' polyclonal cell line was obtained from
peripheral blood of an adult healthy donor. These cells were further purified to generate the
T1 and T2 cell lines.
For expansion, cells were plated in 96-well V-bottomed microtiter plates on a feeder layer
containing an EBVtransformed B cell line (LAZ 388) plus irradiated allogenic lymphocytes.
Cultures were fed every 3 d with lymphocyte-conditioned medium containing IL-2 .
Immunofluorescence Assays and Cytofluometric Analysis.
￿
Studies on "fresh" lymphocytes were
performed usingmonocyte-depleted cell fractions extracted by Ficoll-Hypaque density gra-
dient centrifugation.
Indirect immunofluorescence assays were performed as described previously (24). Cells
were incubated with predetermined saturating concentrations of antibody plus fluorescein-
conjugated goat anti-mouse serum. For double-color assays, cells were stained with fluorescei-
nated BMA031 (IgG2b) mAb and unconjugated anti-A13 (IgGI); reactivity of the latter re-
agent was revealed by a phycoerythrin-conjugated goat anti-mouse serum specific for the
IgG1 subclass.
For PBL and cultured cells, samples containing 5 x 104 and 5 x 103 cells, respectively,
were analyzed on the Epics C flow cytometer (Coulter Electronics Inc., Hialeah, FL). In the
experiments where the functional effects of the antibodies have been tested, cells were incu-
bated overnight with the relevant reagent at the predetermined saturating concentration. Im-
munofluorescence assays on the treated cells were performed in parallel.
mAbs.
￿
Anti-NKTa mAb recognizes an infrequent a/,Q clonotypic determinant (24). Anti-
TiyA mAb (16) is specific for a Vy9-encoded epitope; it delineates a subset including N37o
of CD3' TCRa//3- PBL (17). Anti-BMA031 mAb, kindly provided by Dr. R. Kurrle
(Behring Co., Marburg, FRG), recognizes a monomorphic determinant of the TCRa//3 re-
ceptor (29). AntiTCR61 mAb (14), kindly provided by Dr. M. Brenner (Dana-Farber Can-
cer Institute, Boston, MA), recognizes a constant epitope of the human TCR-S protein.
AntiTCR-y/S-1 (13), which reacts with a Cy determinant, was generously given by Dr. J.
Borst (Netherlands Cancer Institute, Amsterdam, Netherlands). Anti-6TCS1 (18), prepared
by the T Cell Sciences Co. (Cambridge, MA), is most likely directed at a VblJbl- (19) and
V61-J62- (20) encoded epitope. The XC3 mAb reacts with the CD2 molecule (unpublished
observations). Anti-CD3 mAb used for immunofluorescence assays was OKT3 (Ortho Diag-MIOSSEC ET AL.
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nostic Systems Inc., Westwood, MA), whereas immunoprecipitation experiments were con-
ducted with an additional anti-CD3 mAb (CD3X3)kindly provided by Dr. A. Bernard (In-
stitut Gustave-Roussy, Villejuif, France). Each mAb was used at a saturating concentration
predetermined by titration curves on positive cloned cell lines.
Immunoprecipitation ofthe 7UR-,y/5 Receptor.
￿
AB12 andTH6.4 cellswere surfacelabeledwith
1251 using a standard lactoperoxidase method and then lysed with a phosphate buffer con-
tainingeither 0.1 or 1.0% Triton X-100, as previously described (16). The lysates were pre-
cleared several times with Staphylococcus A suspension as well as irrelevant antibodies; the
specific immunoprecipitation was carried out overnight at VC with either antiTiVb2 mAb
coupledto bromocyanogen-Sepharose beadsforlysates obtained with high detergent concen-
tration or anti-CD3X3 mAb coupled to protein A-Sepharose beadsforlysates obtained with
a low concentration of detergent. SDS-PAGE analysis was performed using 10% polyacryl-
amidegels either under nonreducingconditions or under reducing conditions afteraddition
of 5% 2-ME.
Cytotoxicity Assays.
￿
Cytotoxic activity of the cells was measured by a conventional 3-h "Cr
release assay using triplicate cultures in V -bottomed plates. The E/T ratiowas 1:1 with 5,000
target cells per well. To test the functional effects of the antibodies, either effector or target
cells were incubated before the assay for 2 h or for 30 min, respectively, using the reagents
at the predetermined saturating concentrations. Percent specific cytotoxicity was calculated
conventionally; SDs were <5%.
Southern and Northern Blot Analyses.
￿
High molecularweight genomic DNA samples (10 NAg)
were digested with Eco RI, XbaI, or PvuII, subjected to electrophoresisthrough 0.770 aga-
rose gels, and blotted in alkaline buffer onto Gene Screen Plus nylon membranes (Dupont
Co., Wilmington, DE). The blots were hybridized in 50% formamide, 5 x SSC, 5x Den-
hardt's solution, 100 lug/ml salmon-sperm DNA, and 10% polyethylene glycol 6000 (PEG
6000)at 42°C for 16 h. They were then washed twice at 65°C for30 min in 0.1 x SSC, 0.1%
SDS.
For the Northern blot analysis, total cytoplasmic RNA (4 kg) was denatured in glyoxal-
dimethyl sulfoxide, separated on 1% agarose gels, transferred to nylon membranes, and hy-
bridized using the same conditions described for the Southern blot analysis.
DNA Probes.
￿
"P-labeled DNA probes were prepared from agarose-purified DNA frag-
mentsby thehexamer-priming method as previously described (10). The V61-specific probe
is an Eco RI-Sac I fragment isolated from clone 0240/38.5 (9), kindly given by Dr. Krangel
(Dana-Farber Cancer Institute). The Cb probe is an Eco RI fragment obtained from the
same clone (9). The Ca probe (a 420-bp Pvu II fragment) and the CO probe (a 400-bp Bgl
II fragment) have been isolated as previously described (17).
Isolation and Characterization of cDNA Clones.
￿
Double-stranded (ds)1 cDNA was synthesized
from poly(A)' RNA derived from the CD3' BMA031' A13' TCR-6I - 6TCSI- T2 cell line.
After size selection and ligation of Eco RI linkers, dscDNA was cloned into the Eco RI site
of the vector X gt10, before the packaging of the X gt10-cDNA hybrids. Screening of 7.5 x
104 recombinant phages was carried out with the Ca probe using standard procedures.
The cDNA inserts were subcloned into the T3T7 transcriptional promotor containing
vector pBS. Nucleotide sequences were determined by the dideoxy chain termination method
using the modified T7 polymerase (Sequenase; United States Biochemical Corp., Cleveland,
OH). cDNA sequencing wasperformed on both strandsusingeither aT3 primer, aT7 primer,
or a Ca-specific primer.
Results
Generation and Characterization of the AntiTiV62 mAb.
￿
Mice were immunized with
the AB12 cells whose phenotypic, functional, and molecular characterization have
been reported previously (10, 17, 27). These TiyA' cells express a'Y chain encoded
by a Vy9JyP-Cyl-rearranged gene. In AB12 lymphocytes, the Vbl segment is in
germline configuration on both chromosomes (10); the functional 6 transcript de-1174
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tected in these cells was found to include a novel VS gene designated VS-AB12 or
VS2 (10), as well as the JSl and the D63 segments (19).
Hybridoma supernatants were screened on the basis of a differential reactivity
between AB12 cells and polyclonal a//3+ T cell lines. A selected hybridoma, now
termed antiTiVS2, was further tested in comodulation experiments, after overnight
incubation of AB12 cells with a saturating concentration of OKT3 mAb. As shown
in Fig. 1, these data indicated that the TiVS2 epitope is linked physically to the CD3
proteins.
The functional effects of the antiTiVS2 mAb on the "non-MHC-requiring" cyto-
toxic activity of AB12 cells was tested using two target cell lines: JM (a T cell leuke-
mia highly susceptible to NK lysis) and U937 (a cell line of histiocytic origin rela-
tively resistant to NK activity). As shown in Fig. 2 A, AB12 lymphocytes exhibited
a strong cytotoxicity against JM cells leading to >507o lysis at a 1 :1 E/T ratio in
a 3-h assay. Treatment of the cellswith antiTiVS2 virtually abrogated this cytotoxic
activity. The blocking effects of antiTiVS2 were similar to those induced by either
OKT3 or antiTiyA mAb, which are both reactive with the receptor complex ex-
FIGURE 1.
￿
Comodulation experiment on AB12 cells. Cells were
preincubated overnight with the OKT3 mAb or with control
medium. Indirect immunofluorescence analyses were then per-
formed with the indicated mAb on OKT3-treated cells (white
areas) and on control cells (black areas).B
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FIGURE 2. Cytotoxic activity of AB12
cells at a 1:1 E/T ratio in a 3-h experiment.
(A) AB12 effector cells were preincubated
with various mAbs before the cytotoxic
assay against JM cells. (B) U937 target
cells were preincubated with mAbs, and
then AB12 cells were added. Series ofmAb
dilutions were tested from the saturating
concentration predetermined in indirect
immunofluorescence assays. (Upper col-
umns) Saturating concentration (1/200 to
1/800 ascites dilutions depending upon in-
dividual mAb); (second columns) halfof the
saturating concentration; (third columns)
1/10; (fourth columns) 1/20.
pressed on thecloned cells. As compared withJM, U937 cells are relatively resistant
to lysis by AB12 lymphocytes (<20% of cytotoxicity at 1:1 E/T ratio); because they
express a Fc receptor (FcRyll), they are useful target cells to test the potential activ-
ity ofa mAb in a "reverse ADCC" system. Again, antiTiVb2 was found to enhance
lysis substantially as well as the other antireceptor antibodies (Fig. 2 B). Note that
the control-irrelevant anti-NKTa mAb (of the IgG1 subclass like antiTiVb2) had
no effect in any of the two series of experiments. Together, these data further sup-
ported the view that antiTiVb2 was directed at a TCR determinant.
Immunoprecipitations with AntiTiVb2 mAb.
￿
To characterize the molecule recognized
by the antiTiVb2 mAb, we performed a series of immunoprecipitations with vari-
ous clones and polyclonal cell lines expressing the y/b receptor. One representative
experiment is shown in Fig. 3. The TH6.4 polyclonal cell line derives from the pe-
ripheral blood of a patient with renal cell carcinoma. More than 95% of these cells
have been found to express the TiVb2 epitope in repeated analyses over a period
of several weeks in culture (data not shown). Note that the TH6.4 lymphocytes do
not carry the TiyA epitope encoded by the Vy9 gene (data not shown). TH6.4 and
AB12 cells were surface labeled with
1251 . Immunoprecipitations from Th6.4 were
performed with antiTiVb2; for AB12 cells, parallel experiments were undertaken
usingeither the CD3X3 anti-CD3 mAb or the antiTiVb2 mAb. Before the CD3X3
precipitations, cell lysis was done in the presence of a low detergent concentration
(0.1% of Triton X-100) to avoid the dissociation of the CD3Ti complex.
Immunoprecipitations from the AB12 clone with the anti-CD3 mAb resulted in
the detection, after SDS-PAGE under nonreducing conditions (Fig. 3, lane a), of
diffuse bands between 18 and 28 kD and of a unique band at 82 kD (corresponding,
respectively, to the CD3 proteins and they/bheterodimer). In parallel, the material1176
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FIGURE 3 .
￿
Immunoprecipitation ofTCRy/b molecules
from CD3' TCRy/b` cell lines by the anti-CD3 and anti-
TiVb2mAbs. Immunoprecipitated material was analyzed
by SDS-PAGE (10% polyacrylamide gel) under nonreducing
(lanes a, b, and c) or reducing (lanes d, e, andj) conditions .
Immunoprecipitations from the AB12 cells were performed
using either the CD3X3 anti-CD3 mAb (lanes a and d) or
the antiTiVb2mAb (lanes band e) . Lysates from theTH6.4
cell line were immunoprecipitated by the antiTiVb2 mAb
(lanes c and e) .
precipitated with antiTiVS2 (Fig. 3, lane b) displayed the same electrophoretic mo-
bility (82 kD), confirming that the antibody is specific forthe CD3-associated recep-
tor. Precipitations performed with antiTiVS2 from theTH6.4 cell line followed by
migration undernonreducing conditions led to the detection oftwo bands at 48 and
45 kD (Fig . 3, lane c) . These results indicated that the TiVS2+ TH6.4 lymphocytes
express a nondisulfide-linked form ofthe y/S receptor with aCy2-encoded y chain.
Note, therefore, that the antiTiVS2 mAb recognizes a y/S determinant whose ex-
pression is not dependent upon the quaternary structure of the receptor (i .e ., C-y1
vs . Cy2) . WhenSDS-PAGE was performed under reducing conditions, y/S proteins
were visualized as three bands at 46, 43, and 41 kD for AB12 cells (Fig. 3, lanes
d, e) and at 46, 43, and 39 kD for TH6.4 cells (lane J) ; in both cases, the 43-kD
band was foundto be predominant . Thesebiochemical results are in line with previ-
ous reports on the -y/S complex (30) .
Gene Assignment of the TiV82 and A13 Antigenic Determinants .
￿
The anti-A13 mAb
was initially found to recognize y/S+ cells that often express the STCS1 determi-
nant while being nonreactivewith anti-13133 mAb (23) . However, the fine specificity
of anti-A13 has remained unknown . Using immunofluorescence assays, we have tested
here a series of y/S+ clones characterized previously (10, 15, 19, 28, and unpublished
data) at both theyand theS loci in an attempt to define theTiVS2 and the A13epitopes .
The antiTiVS2mAb was generated against AB12 cells that express a TiyA' V9-
JP-Cl-encodedychain and a V2-D3J1-C-encoded S chain (10, 19). Immunoprecip-
itationexperiments (Fig . 3) have indicated that the TiVS2 epitope can be associated
with either type ofCy segment . Theclonal analysis showed that the majority (seven
of eight), but not all, ofV9JP TiyA+ clones react with the antibody (Tables I and
II) . Indeed, the TiyA' F6C7 cells are TiVS2 - . The TiyA - G6-cloned cells, whichMIOSSEC ET AL.
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TABLE I
Phenotypic Analysis of CD3+ TCR-y16' Clones
Reactivity ofcultured cell lines with specific rnAbs was assessed by indirect im-
munofluorescence assays followed by cytofluorometric analysis. + , X95% ; - ,
<5% .
are recognized by the antiTiVS2 reagent, display at the 'Y locus (Table 11) a V4Jl
rearrangement on one chromosome, while the other one is in germline configura-
tion. Together, these data suggested that the antiTiVS2 mAb does not react with
a 'y chain determinant. In contrast, the reagent was found to recognize all cloned
cell linesdisplaying a rearrangement involvingthe VS2 gene (TablesIand II): among
the 16 clones studied, the eight expressing the TiVS2 epitope (G6, AB12, BD, BG,
BK, BO, BS, and BX) have rearranged the VS2 segment while being in germ-line
configuration for VS1. Together, there was a strict correlation between the expres-
sion ofthe TiVS2 epitope and therecombination ofthe VS2 gene segment. Further-
more, an in-frame message corresponding to the 5.5-kb Eco RI V62-D3-j61 rear-
rangement has been shown previously to be transcribed in the TiVS2+ AB12 cells
(10). Finally, a message corresponding to a 7-kb Eco RI V62-(D)JS3 rearrangement
(17) has been shown to be expressed productively in the TiVS2+ G6 cells (19). Thus,
it is most likely that antiTiVS2 is specific for a V62-encoded epitope (and not a
VS2/J determinant).
Testingthe anti-A13 mAb on the present series of cloned cell lines confirmed that
its reactivity was restricted to a fraction of y/S+ cells. It was also found that the re-
activity of anti-A13 is not dependent upon the use of a unique Cy segment because
both the Cy1+ F6C7 andJ2D2 cells and various Cy2+ clones (A2C12,J2B7, N2All)
express the corresponding epitope (Tables I and II); furthermore, the six A13+
clones tested (F6C7, A2C12, JIF1, J2B7, J2D2, and N2A11) use distinct Vy genes.
In contrast, these six cells display a VS1 rearrangement. One of the A13+ clones
(F6C7) is STCS1 -; it was shown previously to surface express a VSlJS3-encoded
Schain (19). Together, these data strongly suggest that anti-A13 mAb recognizes the
Clones OKT3 BMA031 TCR-61 Ti-yA TiVS2 A13 STCSl
G6 + - + - + - -
AB12 + - + + + - -
BD + - + + + - -
BG + - + + + - -
BK + - + + + - -
BO + - + + + ND -
BS + - + + + - -
BX + - + + + - -
F6C7 + - + + - + -
A2C12 + - + - - + +
JIF1 + - + - - + +
J2B7 + - + - - + +
J2D2 + - + - - + +
N2All + - + - - + +
A2E9 + - + - - - -
N1C3 + - + - - - -1178
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TABLE II
Rearrangements on y and 8 Loci in a Panel of CD3' TCR-y/8+ Clones
Rearrangements were determined by Southern blot analysis on genomic DNA
(10, 19, 26, and unpublished data). G, germ-line position; D, deleted.
' y locus rearrangements on both chromosomes detected with pH60Jy probe.
1 Use of Cy segment deduced from SDS-PAGE analysis (i.e ., disulfide-linked
vs. non-disulfide-linked dimer.
5 S locus rearrangements detected with the VS2 probe.
II b locus rearrangements detected with the VSl probe.
productoftheVbl segment exclusively, as opposedto anti-bTCS1, which reacts with
cells surface expressing Vb1'Jbl+ chains (19) or Vbl+Jb2+ chains (20).
Using the Anti-"I and Anti-V62 mAbs to Characterize the y/b+ Fraction in Peripheral
Blood. The respective expression, in circulating lymphocytes, ofthe Vb1, the Vb1-
Jbl/Jb2, and the Vb2 gene segments wasreassessed hereusingtherelevant antibodies,
namely anti-A13, anti-bTCSI, and antiTiVb2. As expected (10), a large majority
(80%) ofthe y/b+ T cells were recognized by antiTiVb2, while b chains, including
a V61-J61 orV61-J62 gene product, were present on only a small (13%) 'Y/b+ subset
(Table III). The summed reactivity ofthe anti-A13 and the antiTiVb2 mAbs was
3.2%, whereas the antiTCRb1 mAb recognized 3.0% ofthe cells in this series of
41 individuals (Table III). Such an advantage (+0.2%) of the anti-(V61 + Vb2)
mAb reactivities over that ofantiTCRb1 was surprising. A detailed analysis ofthe
results indicated that in 13 of 41 donors, the sum of Vbl + Vb2 exceeded the CS
expression in a significant fashion ranging from 0.5 to 2.8%.
Expression of the A13 Antigenic Determinant Is not Restricted to ylb+ T Lympho-
cytes. Several hypotheses could be made to explain this apparent discrepancy, in-
cluding a crossreactivity of the anti-A13 mAb with, for example, other Vencoded
TCR epitopes. In any case, it was important to assess whether the antibody recog-
nized cells expressing they/b receptor in an exclusive fashion. Thus, we performed
a series ofdouble-color immunofluorescence analyseswith anti-A13 and anti-BMA031,
a reagent specific foraconstant epitopeofthe a//3 receptor. A representative experi-
y locus S locus
Clones Chl" Ch2' Cyl V625 VSlll
G6 V4J1 G Cyl G/R (13) G/G
AB12 V9-JP V10JP1 Cyl G/R (11) G/G
BD V9-JP V10JP1 Cyl D/R (11) G/G
BG V9-JP V10-JP1 ND G/R (11) G/G
BK V9-JP V10-JP1 ND G/R (11) G/G
BO V9-JP V8-J1 ND G/R (11) G/G
BS V9-JP V10-JP1 Cyl G/R (11) G/G
BX V9-JP V10-JP1 Cyl D/R (11) G/G
F6C7 V9-JP V3-J1 Cyl D/R (ll) G/R (13)
A2C12 V8-J2 Vll J2 Cy2 D/G G/R (l l)
JIF1 V4-J2 V9-J2 ND D/G G/R (11)
J2B7 V2-J2 V3-J2 Cy2 D/R (11) G/R (11)
J2D2 V2-J1 G Cyl D/G G/R (11)
N2A11 V3-J2 V3-J2 Cy2 D/R (6.5 kb) G/R (11)
A2E9 V2-J2 V4-J2 Cy2 G/G G/G
NIC3 V10J2 ND Cy2 G/G G/GMIOSSEC ET AL.
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TABLE III
Immunofluorescence Analysis of PBL
Percent of positive cells was determined by indirect immunofluorescence. V6l
+ V52 represents the summed reactivities of the anti-TiVb2 and anti-A13
mAbs.
* The anti-TCR-b1 reactivity is designated 100%, the other numbers are cal-
culated as compared relative percentages.
Donors TiVb2 A13 bTCSl TCR-61 Vbl + V62
1 2.5 <0.1 <0.1 3.4 2.5
2 1 .9 <0.1 <0.1 2.3 1 .9
3 0.4 0 .2 0.1 0.6 0.6
5 1 .3 0.3 <0.1 1 .6 1.6
6 11 .0 0.4 <0.1 12.0 11 .4
7 1 .5 0.7 0.2 2.5 2 .2
9 2.0 0.8 0.4 2.2 2 .8
10 2.9 1 .3 0.7 3.8 4.2
11 6.5 0.4 0.1 6.9 6.9
12 1 .5 0.7 0.4 2.2 2.2
15 2 .7 0.5 0.3 2.8 3 .2
16 0.3 1 .3 1 .3 1 .9 1 .6
17 2 .3 0.3 0.3 3.0 2 .6
18 4.3 0.5 <0.1 4.6 4.8
19 1 .5 0.4 <0.1 1 .9 1 .9
20 0.9 0.9 0 .6 1.4 1 .8
21 3.0 1 .4 0.9 3.9 4.4
22 3.1 0.7 0.2 3 .5 3 .8
23 0.5 0.5 0.3 1 .2 1 .0
24 1 .3 1 .0 0.3 1,6 2.3
25 3.1 1 .1 0.6 4.0 4.4
26 2.3 0.9 0.4 2.8 3.2
27 1 .5 0.5 0.1 1.5 2.0
28 3.8 0.9 0.5 4 .1 4.7
29 0.7 0.2 0.1 0.9 0.9
30 1 .2 1 .3 1 .1 3 .0 2.5
31 1 .5 0 .2 0.4 2.5 1 .7
32 1 .9 1 .3 0.5 3.7 3.2
33 11 .3 1 .0 0.9 13.4 12.3
34 2 .2 0.2 <0 .1 3.0 2.4
35 0.6 0.5 0.3 0.9 1.1
36 0.6 0.4 0.2 0.8 1.0
37 2 .5 1 .3 1 .0 3.3 3.8
38 3 .1 1 .3 0,6 3.9 4.4
39 2 .8 1 .1 0.5 3.1 3 .9
40 1 .7 0.8 0 .6 1 .9 2.5
41 1 .0 0.8 0 .2 1 .4 1 .8
4 0.4 1 .1 0.3 0.7 1 .5
8 1 .2 3.4 0.3 1 .8 4.6
13 1 .2 1 .0 0.5 1 .3 2.2
14 2.0 1 .2 0.7 2.1 3.2
Mean 2.4 0.8 0.4 3 .0
SD 2.3 0.6 0.3 2.5
Percent* 80 27 13 1001180
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ment (Fig . 4) shows the results obtained with donors 11, 14, and 32 . These three
individuals were tested on the basis of the summed (VS1 + VS2) reactivity com-
paredwith that ofantiTCRS1 (donor 32, -0.5%; donor 11,0% ; donor 14, +1.1%) .
In each of these donors where expression of the CS segment was greater, equal, and
inferior, respectively, to that of the VSl plus VS2 segments, a minor but clearly de-
tectable BMA031+ A13 + cell population was identified (Fig . 4) .
To understand this phenomenon, we further studied the donor (no . 8) who dis-
played the largest (VSl + V62)/CS difference (TCRSl, 1.8% ; A13, 3.4% ; STCSI,
0.3% ; TiVS2, 1.2% ; [VS1 + V621-C6, 2.8%) . A13+ PBL from this individual were
purified by cell sortingprocedures after treatment with thecorrespondingantibody.
The sorted cells were stimulated with PHA and expanded in the presence of IL-2 .
On day 15, cultured lymphocytes were analyzed with a series of mAbs . As shown
in Fig . 5 A, all these cells were A13+ while 85% were BMA031 + WT31 + (i .e ., a/(3+),
and 15% were TCRS1+ TCR-y/S-1 + (i.e ., -y/S+) .
These data suggested that the A13 epitope may be expressed on a//3 receptors .
To analyze this observation, the TCRS1+ A13+ and the BMA031 + A13+ lympho-
cytes were purified from the cell line with an additional round of cell sorting . After
in vitro expansion, the secondary cultures (termed T1 and T2) were phenotyped
on day 25 . The quality of the purification was satisfactory with respective percent-
ages ofTCRS1+ and BMA031 + lymphocytes >95O Io in the relevant corresponding
fractions (Fig . 5, Cand B, respectively) . T2 cells were found to be CD3+BMA031 +
WT31+ TCRS1 - TCR-y/5-1- (Fig . 5 B) . There was a typical bright expression of
the CD8 molecule on all the a/a+ cells, while CD8 was present at low density on
only 30% of they/S+ cells . Note that a substantial number (25%) of the Tl TCR-
S1+ cells coexpressed the Ti7A and the STCSl epitopes (Fig . 5 C) . Such an associ-
ation is infrequent in peripheral blood of most individuals (10, 15) .
The VSl Gene Segment Is Productively Transcribed with Either the Ca or the CS Seg-
ment .
￿
DNA andRNA were extracted from either the A13 + BMA031+ (T2 cell line)
FIGURE 4 .
￿
Double-color immunofluorescence analysis ofPBL . The x-axis shows loge, green
fluorescence intensity obtained with fluoresceinated anti-BMA031 mAb . The y-axis represents
logo red fluorescence intensity obtained with anti-A13 antibody plus phycoerythrin-conjugated
goat anti-mouse IgG1 serum . A, B, and C show the results for PBL from donors 11, 14, and
32, respectively.A B C
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FIGURE 5.
￿
Phenotypic analyses ofpolyclonal
cell lines from donor 8 performed by indirect
immunofluorescence experiments. (A) The
A13' cell line derived from PBL; (B) the
BMA031' cells (T2 cell line) derived from
the A13' cell line; (C the TCRSl' cells (TI
cell line) derived from the A13' cell line.
or the A13' TCRS1 ` (T1 cell line) cultured cells in order to study the genes encod-
ing the TCR chains expressed by the respective lymphocyte fractions.
For Southern blots analyses, we used a C6 and a VS1 probe (see Materials and
Methods). The K562 myeloid cell line was tested to detect the germ-line positions;
TI and T2 cells were studied in parallel. The CS segment was found to be deleted
from both Eco RI and Xba I restriction fragments in the T2 cell line, while 3.5-kb
Eco RI and 9.5-kb Xba I germ-line signal were detected in both K562 and TI cells
(Fig. 6, C and D). With the V61 probe, germ-line bands were found in K562 cells
at 3 and 23 kb on Eco RI and Pvu II fragments, respectively. As shown in Fig. 6,
A and B, one germ-line signal was detected in both TI and T2 cells. On the second
chromosome, the V81 gene segment was rearranged in both cell types. For T1 cells,
the V51 rearrangement corresponded to the expected (given the fact that TI cells
are STCSI +) well-defined VlJl, 3.3-kb Eco RI, and 10-kb Pvu II signals (9). For
T2 cells, a rearrangement was detected as a5.4-kb Eco RI anda 12-kb Pvu II band.
Experiments were also performed with the pH60Jy probe (6) with DNA from T1
and T2 cells; several rearranged bands were found in each case, indicating both cell
lines are polyclonal (data not shown).
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FIGURE 6 .
￿
Southern blot anal-
ysis with DNA extracted from
the K562, TI, andT2 cell lines .
DNA samples were digested
with Eco RI (A and C), Pvu II
(B), orXba I (D) . (A andB) Hy-
bridization with theV61 probe;
(C and D) hybridization with
the CS probe .
For Northern blot analyses, we used aCu and a C/3 probe in addition to the CS
and V61 probes . RNA was prepared from Tl and T2 cells . ATCR61 ` 6TCS1'
cloned cell line, termed A2C12, was used as a positive control for the transcription
of the V61 gene segment . AfterCu hybridizations, a full-length 1.6-kb message was
found in T2 cells, while a 1.3-kb truncated transcript was detected in both A2C12
and T1 lymphocytes (Fig . 7 A) . Results obtained with the Co probe were similar
with a full-length (1.3 kb) transcript in T2 cells and a truncated signal (1.0 kb) in
the others (Fig . 7 C) . As expected from Southern blots that showed a deletion of
this segment, there were no detectable transcripts hybridizing with the C6 probe
in the T2 cells(datanot shown) . For A2C12 and TI cells, theC6 signals (not shown)
were identical to those obtained with the V61 probe, which detected the two well-
characterized 2 .2- and 1.3-kb bands corresponding to distinct polyadenylations of
FIGURE 7. Northern blot anal-
ysis with RNA extracted from
the A2CI2, TI, and T2 cell
lines . RNA samples were hy-
bridized with theCa probe (A),
the V61 probe (B), and the CS
probe (C.MIOSSEC ET AL.
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the 6 chain transcripts. In T2 cells, the VSl hybridization led to a distinct 1.6-kb
signal (Fig. 7 B), which corresponds to the size of the full-length a chain transcript.
Note that CS is undetectable in T2 cells while a germ-line V61 band is present
(Fig. 6, C and D). These results suggest that, at least in some of these cells, rear-
rangements have occurred in the a locus on both chromosomes. It is therefore likely
that an additional V segmentlocateddownstream ofVSl has been used in theother
recombination.
To demonstrate unequivocally that the V61 gene segment is transcribed with the
Ca segment, we prepared an expression library froth the T2 cells that were screened
with the Ca probe. Three positive cDNAs, which included 85% of the V segment
for the longest and 35 o 7o for the shortest, were sequenced. In each case (data not
shown), 100% homology was found with the original V61 sequence (9). The 3' end
of the cDNAs included aJa segment, termed AC24 (31), and the Ca segment also
with 10017b homology to these previously reported sequences (data not shown).
Discussion
We report here thecharacterization of twomAbs directed at the TCR-y/S hetero-
dimer. In earlier series of experiments, multiple CD3' TCR-a/o- cloned cell lines
derived from human peripheral blood have been analyzed for rearrangements and
transcription ofthe genes encoding their TCR-y and TCR6chains. These lympho-
cytes have also been tested with the available antiTCR mAbs, such as antiTCR-Sl,
antiTiyA, or anti-STCSI . Furthermore, expression libraries were produced from
some of these clones, which led to the molecular cloning of the respective 'Y and S
transcripts (19). This well-defined cell panel (10, 15, 19, 28, and unpublished data)
can now be used to assess the fine specificity of novel antiTCR antibodies by simple
immunofluorescence analyses. Thus, testing the reactivity ofanti-A13 and antiTiVS2
on the clones led to the conclusion that they recognize V61 and VS2 gene products,
respectively.
An mAb, designated anti-BB3, has been reported previously (21). Its reactivity
on circulating lymphocytes correlated with the surface expression ofdisulfide-linked
y/6 dimers. It was therefore postulated that the reagent mayrecognize aCyl-encoded
epitope (21, 22). Analyses of ourclones did not support this initial workinghypothe-
sis, rather suggesting a VS2 reactivity (10, 19). With the present characterization
ofthe antiTiVS2 mAb, this pointcanbe concluded definitely. Indeed, we have stud-
ied here a polyclonal cell line, Th6.4, that displays virtually 100% reactivity with
both antiTiVS2 and anti-BB3 mAbs (data not shown). Using the former reagent
to immunoprecipitate the receptor complex, TH6.4 cells were found to surface ex-
press a non-disulfide-linked, i.e., Cy2-encoded, y chain.
The TH6.4 line, developed from blood of a patient with renal cell carcinoma,
has been very useful to studythe specificity ofthe antibodies. In addition, its charac-
terization has shown that there are no sterical constraints prohibiting the associa-
tion of a VS2+ S chain and a Cy2+ y chain in a non-disulfide-linked receptor. Nev-
ertheless, such association is likely to be infrequent in peripheral blood because all
other VS2+ peripheral cells derived from normal donors that we and other groups
(10, 21) have studied were found to carry a Cyl' (most often Vy9') disulfide-linked
receptor.
In the original report on the anti-A13 mAb, it was found that this reagent recog-1184
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nizes a 13113- TCRy/S+ peripheral blood cell fraction partially reactive with anti-
6TCSI (23). Our present findings are in line with these initial studies. In light of
the gene assignment proposed here for anti-A13, i .e., VSl, one can explain why a
minority of TCRy/S+ A13+ circulating lymphocytes are 6TCS1 - . The latter anti-
body reacts with either V61-j61 (19) or Vb1JS2 chains (20); the A13+ 6TCS1 - frac-
tion is likely to include infrequent cells expressing V61-J63 receptors such as the pre-
viously described F6C7 clone (19).
We have used the series of antibodies specific for the 6 chain to reassess the distri-
bution of the VS segments in the circulating TCRy/S+ fraction of adult healthy do-
nors. In a series of 41 individuals, the summed reactivity of antiTiV62 plus that
of anti-STCS1 (2.4 + 0.4 = 2.8%) almost reached that of antiTCR61 (3.0%). Evi-
dently, such a sum does not account for the minor fractions of VSl+ lymphocytes
using J63. These data further support the view that the V61 and the VS2 gene seg-
ments are used in a virtually exclusive fashion by peripheral cells of most individu-
als, while VS2 is largely predominant.
Double-color immunofluorescence experiments showed the existence of a size-
able BMA031+ A13 + peripheral lymphocyte subpopulation in all individuals tested
in this study. The development of the T2 polyclonal cell line has allowed us to ana-
lyze this observation. Northern blots demonstrated that V61 is indeed transcribed
with the Ca segment in these BMA031 + A13+ cells. This has been confirmed by
sequencing three clones isolated from a T2 cell cDNA library with the Ca probe.
The cDNA V regions showed 100% homology with the original V61 sequence.
In the mouse, nine families of VS segments have been identified. Five of them
are quite distinct from the previously described Va genes (32-35). Four are closely
related to Vci segments. Indeed, the murine cDNAs Z68, VM23, 52.3, and KN25
isolated from distinct thymic libraries have 99, 94, 97, and 95% nucleotidic homol-
ogy to the TAI, TA27, TA65, and FN1.18 Va gene segments, respectively (33-36).
It is therefore clear that murine "V8" and "Va" genes are partially overlapping sets.
In the human, there has been only one similar observation. An infrequently used
gene segment displaying 96% homology to Va6.1 (HAP01 cDNA clone) was found
to be used in a y/S receptor (12). The 11 nucleotidic differences between this V6
(designated VS4 by Takihara et al. [11]) and Va6.1 were found to be dispersed through-
out the gene segment. Note that Southern blots performed with the VS4 probe led
to the detection of two bands with common restriction enzymes (11), suggesting that
this V segment is a member of a family.
V61 has been the first human gene segment shown to rearrange at the 6 locus
(9). Further studies have indicated that it was the predominant segment used in thy-
mic 6 chains while present on a sizeable minority of peripheral cells with the y/6
receptor (15, 30, 37, 38). Sequence comparison of V61 with that of previously re-
ported Va segments showed that it matches a human Va consensus in 75% of the
residues (9); at the protein level, it is distantly related (57% identity) to the human
Va sequence PGA5 (9). As opposed to other examples discussed here, V61 has no
strong homology with other known V sequences. This correlates with the fact that
the V61 probe detects only one band in genomic DNA digested with a variety of
restriction enzymes (9, 11). Together, it is most likely that V61 defines a one-member
family. Our present experiments indicate that this unique V segment, representingMIOSSEC ET AL.
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one of the two major VS genes, is in fact used in either type of receptor structure
(i.e., a/a and -y/S) .
Southern blots performed with a Jy probe in the T2 cells showed that the line
is polyclonal while theVS1 probe detected a unique rearranged band. These results
(in line with the sequencing data where the sameJa segment was found in the three
cDNA clones) support the view that BMA031+ A13+ cells may preferentially use
certainJa segments. Furthercharacterization ofthe corresponding lymphocyte sub-
set in series of individuals will have to address this point.
We have originally identified (10), in acloned cell line termed AB12, aVS segment
(VS2) that is used by -80% of peripheral TCRy/S+ lymphocytes (Table III). The
same sequence has been reported by other groups (11, 39). It does not display a
significant homology with a Va consensus (10). Using antiTiVS2 mAb, which rec-
ognizes the corresponding gene product, we have performed double-color im-
munofluorescence assays in order to potentially identify BMA031 + TiVS2+ lympho-
cytes. Such cells were undetectable in PBLfrom five normal donors (datanot shown).
It is therefore likely that VS2 represents a "S-specific" (or "highly selective") gene
segment.
We and others have shown that the combinatorial diversity of the y/S receptors
expressed in human circulating lymphocytes is very limited (15, 21). This may pro-
vide a unique opportunity to easily assess, with a relatively limited panel of specific
mAbs, the molecular structure of TCR chains expressed by lymphocytes in both
normal and immunopathological situations. For example, it has been shown, using
antiTi,yA, that cells expressing V9+ y chains are present with high frequency in
the altered joints of patients with chronic rheumatoid arthritis (40, 41). When the
role of y/8+ T lymphocytes in immune responses is better understood, potential
structure/function correlations may be ofclinical interest. Anti-A13 and antiTiVS2
will further contribute to complete apanel of useful antibodies. However, theformer
reagent will have to be used in association with antibodies directed at constant re-
gions of the receptors for appropriate interpretation of the data.
Summary
In the present study, we have characterized the reactivity of two mAbs that are
directed at the humanTCRy/& These reagents, designated anti-A13 and antiTiVS2,
were found to recognize antigenic determinants encoded by the TCR VS1 and VS2
gene segments, respectively. Immunofluorescence analyses performed with the anti-
bodies confirmed that, in the TCR-y/S+ cell subpopulation, the expression ofVS2;
8 chains is largely predominant, as compared with the VS1' counterparts. How-
ever, these experiments led to an apparently discrepant finding. Indeed, the total
number ofcells recognized by the anti-A13 plus the antiTiVS2 antibodies wasoften
greaterthan that detected with antiTCR-S1, a reagentspecific foraconstant epitope
of the human S chain. Further investigation showed the presence of a sizeable pe-
ripheral lymphocyte subset coexpressing the BMA031 and the A13 epitopes. Be-
causethe former antibody is known to recognizean invariant antigenic determinant
of the TCR-a/o dimer, these results suggested that the VS1 gene segment may be
expressed with either CS or Ca. This hypothesis was confirmed using T2, an IL-2-
dependent BMA031 + A13+ polyclonal cell line developed from peripheral blood of1186
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a healthy adult donor. Indeed, T2 cells were found to have productively rearranged
the VS1 gene. Together, results of Northern blot analysis and cDNA cloning indi-
cated that VSl was expressed in these cells as part of a 1 .6-kb full-length message
including Jai-Cci segments.
Receivedfor publication 27June 1989 and in revisedform 9 November 1989.
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